Every 8-K that Corgi IP Licensing & Royalties ETF (PTNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PTNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTNT filings page.
Palatin Technologies reported that underwriters exercised their over-allotment option tied to its recent public offering. The underwriters purchased 280,615 common shares at $6.50, plus pre-funded warrants for 84,000 shares at $6.50, and the company issued accompanying Series J warrants to buy up to 364,615 shares at $6.50 and Series K warrants to buy up to 364,615 shares at $8.125. This added approximately $2.37 million in gross proceeds, before fees and expenses.
After giving effect to the over-allotment exercise, total gross proceeds from the offering rose to approximately $18.2 million. Palatin also filed a legal opinion covering the securities and noted a related press release.
Palatin Technologies (PTNT) entered an underwriting agreement for a public offering of 2,430,769 shares of common stock (or pre-funded warrants in lieu) together with Series J and Series K warrants at a combined public offering price of $6.50 per share and accompanying warrants. The company expects gross proceeds of approximately $15.8 million, with a 45-day option for up to 364,615 additional shares. Closing is expected on or about November 12, 2025, subject to the resumption of trading on NYSE American.
Series J Warrants have a $6.50 exercise price and an expiry tied to the earlier of 18 months or 31 days after FDA acceptance of an IND for an in-house obesity treatment compound. Series K Warrants have an $8.125 exercise price and a five-year term, subject to early termination if Series J conditions aren’t met before the FDA exercise period ends. The company noted a prior 1-for-50 reverse split and submitted pro forma materials supporting compliance with the NYSE American $6.0 million stockholders’ equity standard, citing $8.8 revenue from a Boehringer Ingelheim collaboration and expected $14.7 million net proceeds. Trading is expected to resume on NYSE American under PTN on November 12, 2025.
Palatin Technologies, Inc. reported that it achieved a research milestone under its collaboration with Boehringer Ingelheim, triggering a €5.5 million ($6.5 million) payment to Palatin. This payment adds to an earlier upfront payment of €2.0 million ($2.3 million) and is part of up to €18.0 million ($21.2 million) in near-term research milestones available under the agreement.
Beyond these near-term milestones, Palatin is eligible for as much as €260 million ($307 million) in success-based development, regulatory, and commercial milestone payments, plus tiered royalties on net sales from any products that emerge from the collaboration. Separately, the company notes that its common stock was found no longer suitable for listing on NYSE American due to a low selling price, was suspended from trading on that exchange on May 7, 2025, and now trades on the OTCQB Market under the symbol “PTNT”.